Top

Published in:

01-08-2016 | Review Article

The emerging roles of Jab1/CSN5 in cancer

Authors: Lin Wang, Jun-Nian Zheng, Dong-Sheng Pei

Published in: Medical Oncology | Issue 8/2016

Abstract

C-Jun activation domain-binding protein-1 (Jab1) not only is full but also a subunit (CSN5) of the constitutive photomorphogenesis 9 signalosome (CSN), which is an evolutionarily conserved and multifunctional protein that involves in controlling cellular proliferation and apoptosis, affecting a series of pathways, as well as regulating genomic instability and DNA damage and repair. The CSN is a highly conservative protein from yeast to human and interacts with the cullin-RING family of ubiquitin ligases so that it could be execute a process of removing NEDD8, a ubiquitin-like polypeptide (deneddylase activity). The role of Jab1/CSN5’s multi-function has been proved as being oncogenic in nature, what is more, Jab1/CSN5 has been confirmed by much evidence that it participates in the carcinogenesis progression and is tightly associated with poor prognosis. However, the biologic implication of Jab1/CSN5 activity during the cancer’s development is unclear. We performed a systematic literature review and assessment from PubMed and Medline databases in this article. Jab1/CSN5 is participate in a lot of biologic responses, including cell proliferation, apoptosis, cell cycle regulation, DNA metabolism, invasion, DNA damage and repair, and recurrence. It also promotes cell transformation and tumorigenesis. In this review, we mainly expound the progress in the function and research advances of Jab1/CSN5 and in untangling the Jab1/CSN5 signaling pathway. Based on these bases, its potential as a therapeutic target for cancer can play a greater role in future cancer treatment.

Chamovitz DA, Wei N, Osterlund MT, von Arnim AG, Staub JM, Matsui M, et al. The COP9 complex, a novel multisubunit nuclear regulator involved in light control of a plant developmental switch. Cell. 1996;86(1):115–21.PubMedCrossRef

Chamovitz DA, Segal D. JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep. 2001;2(2):96–101. doi:10.1093/embo-reports/kve028.PubMedPubMedCentralCrossRef

Gusmaroli G, Figueroa P, Serino G, Deng XW. Role of the MPN subunits in COP9 signalosome assembly and activity, and their regulatory interaction with Arabidopsis Cullin3-based E3 ligases. Plant Cell. 2007;19(2):564–81. doi:10.1105/tpc.106.047571.PubMedPubMedCentralCrossRef

Wei N, Deng XW. The COP9 signalosome. Annu Rev Cell Dev Biol. 2003;19:261–86. doi:10.1146/annurev.cellbio.19.111301.112449.PubMedCrossRef

Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature. 1999;398(6723):160–5. doi:10.1038/18230.PubMedCrossRef

Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, et al. Jun activation domain binding protein 1 expression is associated with low p27(Kip1) levels in node-negative breast cancer. Clin Cancer Res. 2003;9(15):5652–9.PubMed

Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tai Y, et al. Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin Cancer Res. 2001;7(12):4130–5.PubMed

Lee MH, Zhao R, Phan L, Yeung SC. Roles of COP9 signalosome in cancer. Cell Cycle. 2011;10(18):3057–66.PubMedPubMedCentralCrossRef

Zhang XC, Chen J, Su CH, Yang HY, Lee MH. Roles for CSN5 in control of p53/MDM2 activities. J Cell Biochem. 2008;103(4):1219–30. doi:10.1002/jcb.21504.PubMedCrossRef

10.

Li J, Gu Z, Li S, Xiao Z, Sun K. Reverse correlation of Jab1 and Smad4 in PANC-1 cells involved in the pathogenesis of pancreatic cancer. Int J Clin Exp Pathol. 2015;8(8):9279–85.PubMedPubMedCentral

11.

Pan Y, Zhang Q, Atsaves V, Yang H, Claret FX. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene. 2013;32(22):2756–66. doi:10.1038/onc.2012.294.PubMedCrossRef

12.

Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, et al. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene. 2010;29(46):6125–37. doi:10.1038/onc.2010.345.PubMedPubMedCentralCrossRef

13.

Claret FX, Hibi M, Dhut S, Toda T, Karin M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature. 1996;383(6599):453–7. doi:10.1038/383453a0.PubMedCrossRef

14.

Bae MK, Ahn MY, Jeong JW, Bae MH, Lee YM, Bae SK, et al. Jab1 interacts directly with HIF-1α and regulates its stability. J Biol Chem. 2002;277(1):9–12. doi:10.1074/jbc.C100442200.PubMedCrossRef

15.

Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, Chang HY. Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet. 2006;38(4):421–30. doi:10.1038/ng1752.PubMedPubMedCentralCrossRef

16.

Guo H, Jing L, Cheng Y, Atsaves V, Lv Y, Wu T, et al. Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis. Hepatology. 2016;63(3):898–913. doi:10.1002/hep.28372.PubMedCrossRef

17.

Xu T, Su B, Wang C, Wang S, Huang H, Pan Y, et al. Molecular markers to assess short-term disease local recurrence in nasopharyngeal carcinoma. Oncol Rep. 2015;33(3):1418–26. doi:10.3892/or.2015.3739.PubMedPubMedCentral

18.

Zhang SN, Pei DS, Zheng JN. The COP9 signalosome subunit 6 (CSN6): a potential oncogene. Cell Div. 2013;8(1):14. doi:10.1186/1747-1028-8-14.PubMedPubMedCentralCrossRef

19.

Wei N, Serino G, Deng XW. The COP9 signalosome: more than a protease. Trends Biochem Sci. 2008;33(12):592–600. doi:10.1016/j.tibs.2008.09.004.PubMedCrossRef

20.

Tran HJ, Allen MD, Lowe J, Bycroft M. Structure of the Jab1/MPN domain and its implications for proteasome function. Biochemistry. 2003;42(39):11460–5. doi:10.1021/bi035033g.PubMedCrossRef

21.

Schwechheimer C, Deng XW. COP9 signalosome revisited: a novel mediator of protein degradation. Trends Cell Biol. 2001;11(10):420–6.PubMedCrossRef

22.

Wolf DA, Zhou C, Wee S. The COP9 signalosome: an assembly and maintenance platform for cullin ubiquitin ligases? Nat Cell Biol. 2003;5(12):1029–33. doi:10.1038/ncb1203-1029.PubMedCrossRef

23.

Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, Schulman BA. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell. 2008;134(6):995–1006. doi:10.1016/j.cell.2008.07.022.PubMedPubMedCentralCrossRef

24.

Busch S, Schwier EU, Nahlik K, Bayram O, Helmstaedt K, Draht OW, et al. An eight-subunit COP9 signalosome with an intact JAMM motif is required for fungal fruit body formation. Proc Natl Acad Sci USA. 2007;104(19):8089–94. doi:10.1073/pnas.0702108104.PubMedPubMedCentralCrossRef

25.

Rosel D, Kimmel AR. The COP9 signalosome regulates cell proliferation of Dictyostelium discoideum. Eur J Cell Biol. 2006;85(9–10):1023–34. doi:10.1016/j.ejcb.2006.04.006.PubMedCrossRef

26.

Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate. 2007;67(7):692–700. doi:10.1002/pros.20543.PubMedCrossRef

27.

Fejzo MS, Godfrey T, Chen C, Waldman F, Gray JW. Molecular cytogenetic analysis of consistent abnormalities at 8q12-q22 in breast cancer. Genes Chromosomes Cancer. 1998;22(2):105–13.PubMedCrossRef

28.

Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525–32. doi:10.1056/NEJM198809013190901.PubMedCrossRef

29.

Dimova I, Orsetti B, Negre V, Rouge C, Ursule L, Lasorsa L, et al. Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis. Tumori. 2009;95(3):357–66.PubMed

30.

Shackleford TJ, Claret FX. JAB1/CSN5: a new player in cell cycle control and cancer. Cell Div. 2010;5:26. doi:10.1186/1747-1028-5-26.PubMedPubMedCentralCrossRef

31.

Kwok SF, Solano R, Tsuge T, Chamovitz DA, Ecker JR, Matsui M, et al. Arabidopsis homologs of a c-Jun coactivator are present both in monomeric form and in the COP9 complex, and their abundance is differentially affected by the pleiotropic cop/det/fus mutations. Plant Cell. 1998;10(11):1779–90.PubMedPubMedCentralCrossRef

32.

Oron E, Mannervik M, Rencus S, Harari-Steinberg O, Neuman-Silberberg S, Segal D, et al. COP9 signalosome subunits 4 and 5 regulate multiple pleiotropic pathways in Drosophila melanogaster. Development. 2002;129(19):4399–409.PubMed

33.

Sharon M, Mao H, Erba EB, Stephens E, Zheng N, Robinson CV. Symmetrical modularity of the COP9 signalosome complex suggests its multifunctionality. Structure. 2009;17(1):31–40. doi:10.1016/j.str.2008.10.012.PubMedCrossRef

34.

Cope GA, Deshaies RJ. COP9 signalosome: a multifunctional regulator of SCF and other cullin-based ubiquitin ligases. Cell. 2003;114(6):663–71.PubMedCrossRef

35.

Dubiel W. Resolving the CSN and CAND1 paradoxes. Mol Cell. 2009;35(5):547–9. doi:10.1016/j.molcel.2009.08.011.PubMedCrossRef

36.

Cope GA, Suh GS, Aravind L, Schwarz SE, Zipursky SL, Koonin EV, et al. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science. 2002;298(5593):608–11. doi:10.1126/science.1075901.PubMedCrossRef

37.

Pan Y, Claret FX. Targeting Jab1/CSN5 in nasopharyngeal carcinoma. Cancer Lett. 2012;326(2):155–60. doi:10.1016/j.canlet.2012.07.033.PubMedPubMedCentralCrossRef

38.

Adler AS, Littlepage LE, Lin M, Kawahara TL, Wong DJ, Werb Z, et al. CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression. Cancer Res. 2008;68(2):506–15. doi:10.1158/0008-5472.CAN-07-3060.PubMedPubMedCentralCrossRef

39.

Pan Y, Yang H, Claret FX. Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer. Cancer Biol Ther. 2014;15(3):256–62. doi:10.4161/cbt.27823.PubMedPubMedCentralCrossRef

40.

Hsu MC, Huang CC, Chang HC, Hu TH, Hung WC. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor γ ligands in vitro and in vivo. Clin Cancer Res. 2008;14(13):4045–52. doi:10.1158/1078-0432.CCR-07-5040.PubMedCrossRef

41.

Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao P, et al. Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma. Cancer Res. 2006;66(17):8581–9. doi:10.1158/0008-5472.CAN-06-0975.PubMedPubMedCentralCrossRef

42.

Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res. 2003;63(11):2977–81.PubMed

43.

Osoegawa A, Yoshino I, Kometani T, Yamaguchi M, Kameyama T, Yohena T, et al. Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features. Cancer. 2006;107(1):154–61. doi:10.1002/cncr.21961.PubMedCrossRef

44.

Yoshida A, Yoneda-Kato N, Kato JY. CSN5 specifically interacts with CDK2 and controls senescence in a cytoplasmic cyclin E-mediated manner. Sci Rep. 2013;3:1054. doi:10.1038/srep01054.PubMedPubMedCentral

45.

Wang Z, Fukushima H, Inuzuka H, Wan L, Liu P, Gao D, et al. Skp2 is a promising therapeutic target in breast cancer. Front Oncol. 2012;1:57. doi:10.3389/fonc.2011.00057.PubMedCentralCrossRef

46.

Cocklin R, Goebl M. Nutrient sensing kinases PKA and Sch9 phosphorylate the catalytic domain of the ubiquitin-conjugating enzyme Cdc34. PLoS One. 2011;6(11):e27099. doi:10.1371/journal.pone.0027099.PubMedPubMedCentralCrossRef

47.

Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3(2):231–4.PubMedCrossRef

48.

Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res. 1997;3(12 Pt 1):2269–74.PubMed

49.

Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res. 1999;59(15):3790–4.PubMed

50.

Pan Y, Zhang Q, Tian L, Wang X, Fan X, Zhang H, et al. Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer Res. 2012;72(7):1890–900. doi:10.1158/0008-5472.CAN-11-3472.PubMedPubMedCentralCrossRef

51.

Kamura T, Hara T, Matsumoto M, Ishida N, Okumura F, Hatakeyama S, et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol. 2004;6(12):1229–35. doi:10.1038/ncb1194.PubMedCrossRef

52.

Launay JM, Herve P, Peoc’h K, Tournois C, Callebert J, Nebigil CG, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med. 2002;8(10):1129–35. doi:10.1038/nm764.PubMedCrossRef

53.

Zhang Q, Tian L, Mansouri A, Korapati AL, Johnson TJ, Claret FX. Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells. FEBS Lett. 2005;579(18):3932–40. doi:10.1016/j.febslet.2005.06.012.PubMedPubMedCentralCrossRef

54.

Hsu MC, Chang HC, Hung WC. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells. Endocr Relat Cancer. 2007;14(3):655–67. doi:10.1677/ERC-07-0077.PubMedCrossRef

55.

Fukumoto A, Tomoda K, Yoneda-Kato N, Nakajima Y, Kato JY. Depletion of Jab1 inhibits proliferation of pancreatic cancer cell lines. FEBS Lett. 2006;580(25):5836–44. doi:10.1016/j.febslet.2006.09.042.PubMedCrossRef

56.

Sang MM, Du WQ, Zhang RY, Zheng JN, Pei DS. Suppression of CSN5 promotes the apoptosis of gastric cancer cells through regulating p53-related apoptotic pathways. Bioorg Med Chem Lett. 2015;25(15):2897–901. doi:10.1016/j.bmcl.2015.05.057.PubMedCrossRef

57.

Reed JC. Bcl-2 family proteins. Oncogene. 1998;17(25):3225–36. doi:10.1038/sj.onc.1202591.PubMedCrossRef

58.

Lee YH, Judge AD, Seo D, Kitade M, Gomez-Quiroz LE, Ishikawa T, et al. Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene. 2011;30(40):4175–84. doi:10.1038/onc.2011.126.PubMedPubMedCentralCrossRef

59.

Brady HJ, Gil-Gomez G. Bax. The pro-apoptotic Bcl-2 family member, Bax. Int J Biochem Cell Biol. 1998;30(6):647–50.PubMedCrossRef

60.

Guo B, Godzik A, Reed JC. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J Biol Chem. 2001;276(4):2780–5. doi:10.1074/jbc.M005889200.PubMedCrossRef

61.

Liu X, Pan Z, Zhang L, Sun Q, Wan J, Tian C, et al. JAB1 accelerates mitochondrial apoptosis by interaction with proapoptotic BclGs. Cell Signal. 2008;20(1):230–40. doi:10.1016/j.cellsig.2007.10.012.PubMedCrossRef

62.

No YR, Lee SJ, Kumar A, Yun CC. HIF1α-induced by Lysophosphatidic acid is stabilized via interaction with MIF and CSN5. PLoS One. 2015;10(9):e0137513. doi:10.1371/journal.pone.0137513.PubMedPubMedCentralCrossRef

63.

Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3(10):791–800. doi:10.1038/nri1200.PubMedCrossRef

64.

Burger-Kentischer A, Finkelmeier D, Thiele M, Schmucker J, Geiger G, Tovar GE, et al. Binding of JAB1/CSN5 to MIF is mediated by the MPN domain but is independent of the JAMM motif. FEBS Lett. 2005;579(7):1693–701. doi:10.1016/j.febslet.2005.01.080.PubMedCrossRef

65.

Lechien JR, Kindt N, Costa Pde A, Chantrain G, Preillon J, Laurent G, et al. MIF in head and neck cancer: a new therapeutic target? Rev Laryngol Otol Rhinol. 2013;134(2):67–74.

66.

Wilson JM, Coletta PL, Cuthbert RJ, Scott N, MacLennan K, Hawcroft G, et al. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology. 2005;129(5):1485–503. doi:10.1053/j.gastro.2005.07.061.PubMedCrossRef

67.

Sun B, Nishihira J, Yoshiki T, Kondo M, Sato Y, Sasaki F, et al. Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res. 2005;11(3):1050–8.PubMed

68.

Ren Y, Law S, Huang X, Lee PY, Bacher M, Srivastava G, et al. Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg. 2005;242(1):55–63.PubMedPubMedCentralCrossRef

69.

del Vecchio MT, Tripodi SA, Arcuri F, Pergola L, Hako L, Vatti R, et al. Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes. Prostate. 2000;45(1):51–7.PubMedCrossRef

70.

Han I, Lee MR, Nam KW, Oh JH, Moon KC, Kim HS. Expression of macrophage migration inhibitory factor relates to survival in high-grade osteosarcoma. Clin Orthop Relat Res. 2008;466(9):2107–13. doi:10.1007/s11999-008-0333-1.PubMedPubMedCentralCrossRef

71.

Meyer-Siegler KL, Vera PL, Iczkowski KA, Bifulco C, Lee A, Gregersen PK, et al. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun. 2007;8(8):646–52. doi:10.1038/sj.gene.6364427.PubMedCrossRef

72.

Savaskan NE, Fingerle-Rowson G, Buchfelder M, Eyupoglu IY. Brain miffed by macrophage migration inhibitory factor. Int J Cell Biol. 2012;2012:139573. doi:10.1155/2012/139573.PubMedPubMedCentralCrossRef

73.

Turtzo LC, Li J, Persky R, Benashski S, Weston G, Bucala R, et al. Deletion of macrophage migration inhibitory factor worsens stroke outcome in female mice. Neurobiol Dis. 2013;54:421–31. doi:10.1016/j.nbd.2013.01.016.PubMedPubMedCentralCrossRef

74.

Rendon BE, Willer SS, Zundel W, Mitchell RA. Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation. Exp Mol Pathol. 2009;86(3):180–5. doi:10.1016/j.yexmp.2009.01.001.PubMedPubMedCentralCrossRef

75.

Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature. 2000;408(6809):211–6. doi:10.1038/35041591.PubMedCrossRef

76.

Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, et al. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2007;26(35):5046–59. doi:10.1038/sj.onc.1210318.PubMedCrossRef

77.

Winner M, Koong AC, Rendon BE, Zundel W, Mitchell RA. Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res. 2007;67(1):186–93. doi:10.1158/0008-5472.CAN-06-3292.PubMedPubMedCentralCrossRef

78.

Kleemann R, Grell M, Mischke R, Zimmermann G, Bernhagen J. Receptor binding and cellular uptake studies of macrophage migration inhibitory factor (MIF): use of biologically active labeled MIF derivatives. J Interferon Cytokine Res. 2002;22(3):351–63. doi:10.1089/107999002753675785.PubMedCrossRef

79.

Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342(6250):705–8. doi:10.1038/342705a0.PubMedCrossRef

80.

Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res. 2003;1(14):993–1000.PubMed

81.

Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000;275(12):8945–51.PubMedCrossRef

82.

Asano K, Vornlocher HP, Richter-Cook NJ, Merrick WC, Hinnebusch AG, Hershey JW. Structure of cDNAs encoding human eukaryotic initiation factor 3 subunits. Possible roles in RNA binding and macromolecular assembly. J Biol Chem. 1997;272(43):27042–52.PubMedCrossRef

83.

Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C, et al. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J. 2001;20(7):1630–9. doi:10.1093/emboj/20.7.1630.PubMedPubMedCentralCrossRef

84.

Larsen M, Hog A, Lund EL, Kristjansen PE. Interactions between HIF-1 and Jab1: balancing apoptosis and adaptation. Outline of a working hypothesis. Adv Exp Med Biol. 2005;566:203–11. doi:10.1007/0-387-26206-7_28.PubMedCrossRef

85.

Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin Cell Dev Biol. 2002;13(1):29–37. doi:10.1006/scdb.2001.0287.PubMedCrossRef

86.

Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003;1(3):E83. doi:10.1371/journal.pbio.0000083.PubMedPubMedCentralCrossRef

87.

Bemis L, Chan DA, Finkielstein CV, Qi L, Sutphin PD, Chen X, et al. Distinct aerobic and hypoxic mechanisms of HIF-α regulation by CSN5. Genes Dev. 2004;18(7):739–44. doi:10.1101/gad.1180104.PubMedPubMedCentralCrossRef

88.

Huang J, Yuan H, Lu C, Liu X, Cao X, Wan M. Jab1 mediates protein degradation of the Rad9-Rad1-Hus1 checkpoint complex. J Mol Biol. 2007;371(2):514–27. doi:10.1016/j.jmb.2007.05.095.PubMedPubMedCentralCrossRef

89.

Doronkin S, Djagaeva I, Beckendorf SK. CSN5/Jab1 mutations affect axis formation in the Drosophila oocyte by activating a meiotic checkpoint. Development. 2002;129(21):5053–64.PubMed

90.

Groisman R, Polanowska J, Kuraoka I, Sawada J, Saijo M, Drapkin R, et al. The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell. 2003;113(3):357–67.PubMedCrossRef

91.

Higa LA, Mihaylov IS, Banks DP, Zheng J, Zhang H. Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol. 2003;5(11):1008–15. doi:10.1038/ncb1061.PubMedCrossRef

92.

Parrilla-Castellar ER, Arlander SJ, Karnitz L. Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex. DNA Repair. 2004;3(8–9):1009–14. doi:10.1016/j.dnarep.2004.03.032.PubMedCrossRef

93.

Shinohara A, Ogawa H, Ogawa T. Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein. Cell. 1992;69(3):457–70.PubMedCrossRef

94.

Tsuzuki T, Fujii Y, Sakumi K, Tominaga Y, Nakao K, Sekiguchi M, et al. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci USA. 1996;93(13):6236–40.PubMedPubMedCentralCrossRef

95.

Sonoda E, Sasaki MS, Buerstedde JM, Bezzubova O, Shinohara A, Ogawa H, et al. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J. 1998;17(2):598–608. doi:10.1093/emboj/17.2.598.PubMedPubMedCentralCrossRef

96.

Acosta JC, Gil J. Senescence: a new weapon for cancer therapy. Trends Cell Biol. 2012;22(4):211–9. doi:10.1016/j.tcb.2011.11.006.PubMedCrossRef

97.

Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J, et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene. 1999;18(34):4808–18. doi:10.1038/sj.onc.1203078.PubMedCrossRef

98.

Doronkin S, Djagaeva I, Beckendorf SK. The COP9 signalosome promotes degradation of Cyclin E during early Drosophila oogenesis. Dev Cell. 2003;4(5):699–710.PubMedCrossRef

99.

Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol. 2010;12(1):54–9. doi:10.1038/ncb2004 (Sup pp. 1–14).PubMedCrossRef

100.

Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007;130(2):223–33. doi:10.1016/j.cell.2007.07.003.PubMedCrossRef

Title: The emerging roles of Jab1/CSN5 in cancer
Authors: Lin Wang
Jun-Nian Zheng
Dong-Sheng Pei
Publication date: 01-08-2016
Publisher: Springer US
Published in: Medical Oncology / Issue 8/2016
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-016-0805-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2016

Biochemical composition of malignant ascites determines high aggressiveness of undifferentiated ovarian tumors

Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc-L-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy

Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial

Targeted re-sequencing of TET2 in Taiwanese patients with myelodysplastic/myeloproliferative neoplasms

Expression analysis of three miRNAs, miR-26a, miR-29b and miR-519d, in relation to MMP-2 expression level in non-small cell lung cancer patients: a pilot study

Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage